Author:
Zolkind Paul,Uppaluri Ravindra
Publisher
Springer Science and Business Media LLC
Reference130 articles.
1. Warnakulasuriya, S. (2009). Global epidemiology of oral and oropharyngeal cancer. Oral Oncology, 45(4–5), 309–316. doi: 10.1016/j.oraloncology.2008.06.002 .
2. Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711–723. doi: 10.1056/NEJMoa1003466 .
3. Ferris, R. L., Blumenschein, G., Jr., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., et al. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. The New England Journal of Medicine, 375(19), 1856–1867. doi: 10.1056/NEJMoa1602252 .
4. Chow, L. Q., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., et al. (2016). Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. Journal of Clinical Oncology, 34(32), 3838–3845.
5. Whiteside, T. L., Letessier, E., Hirabayashi, H., Vitolo, D., Bryant, J., Barnes, L., et al. (1993). Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Research, 53(23), 5654–5662.